Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus -

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - everolimus - tablet - 1 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 0.25mg (drug substance stabilised with butylhydroxytoluene);  ;   - tablet - 0.25 mg - active: everolimus 0.25mg (drug substance stabilised with butylhydroxytoluene)     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - certican is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving an allogenic renal or cardiac transplant and in adult patients receiving an allogenic hepatic transplant (see precautions).

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 0.5mg (drug substance stabilised with butylhydroxytoluene);  ;   - tablet - 0.5 mg - active: everolimus 0.5mg (drug substance stabilised with butylhydroxytoluene)     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - certican is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving an allogenic renal or cardiac transplant and in adult patients receiving an allogenic hepatic transplant (see precautions).

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 0.75mg (drug substance stabilised with butylhydroxytoluene);  ;   - tablet - 0.75 mg - active: everolimus 0.75mg (drug substance stabilised with butylhydroxytoluene)     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - certican is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving an allogenic renal or cardiac transplant and in adult patients receiving an allogenic hepatic transplant (see precautions).

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 1mg (drug substance stabilished with butylhydroxytoluene);  ;   - tablet - 1 mg - active: everolimus 1mg (drug substance stabilished with butylhydroxytoluene)     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - certican is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving an allogenic renal or cardiac transplant and in adult patients receiving an allogenic hepatic transplant (see precautions).

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - everolimus 0.25 mg - tablet

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - everolimus 0.5 mg - tablet

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - everolimus 0.75 mg - tablet

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - everolimus 1 mg - tablet